3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
8
Prostatic Neoplasms
5
Polycystic Ovary Syndrome
5
Multiple Myeloma
5
Colorectal Neoplasms
5
Small Cell Lung Carcinoma
4
Rectal Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Fibrosis
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Intraductal, Noninfiltrating
2
Carcinoma, Hepatocellular
2
Breast Carcinoma In Situ
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Venous Thromboembolism
1
Urinary Bladder Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Thrombosis
1
Sprains and Strains
1
Smoldering Multiple Myeloma
1
Sepsis
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Interventions
Sirolimus
9
Everolimus
5
Imatinib Mesylate
2
temsirolimus
1
saracatinib
1
nintedanib
1
carbon-11 acetate
1
Valproic Acid
1
Sugars
1
Simvastatin
1
Resveratrol
1
Octreotide
1
Loratadine
1
Letrozole
1
Immunoglobulin G
1
Hydroxychloroquine
1
Glutamine
1
Doxycycline
1
Disulfides
1
Cetuximab
1
Celecoxib
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lymphangioleiomyomatosis
×
Simvastatin
×
Clear all
NCT02061397
2020-08-25
SOS
University of Pennsylvania
Phase 1/2
Completed
10 enrolled
6 charts